XXXX effects on subjective and psychosexual well-being, in a randomised @entity0 study comparing high-dose and standard-dose chemotherapy.

@entity1 @entity0 @entity440 @entity353 @entity458 @entity53 @entity546 @entity25
To evaluate the impact of @entity440 on subjective and psychosexual well-being in @entity0 @entity1 in relation to type of prior chemotherapy and menopausal status. Longitudinal interview study in @entity0 @entity1 during and after adjuvant @entity440 use. Menopausal status was defined by last menstrual period and serum @entity53 and FSH levels. Gynaecology outpatient clinic, Tertiary Referral Hospital, January 1995 to September 1999. @entity0 @entity1 <56 years of age, participating in a randomised trial comparing adjuvant high-dose (n=45) and standard-dose (n=53) chemotherapy, followed by radiotherapy and @entity440 . Relative incidence and correlation of subjective and @entity458 during and after @entity440 . During @entity440 the most frequent complaints were hot flushes (85%), disturbed sleep (55%), @entity546 (47%), @entity458 (44%) and musculo-skeletal symptoms (43%). Disturbed sleep correlated with hot flushes (P<0.0005) and concentration problems (P<0.05). Decreased sexual interest correlated with @entity353 (P<0.0005). In the high-dose group more @entity1 became postmenopausal (95% vs 33%) and more @entity1 reported symptoms than in the standard-dose group (P<0.05). After discontinuation of @entity440 , symptoms decreased significantly. However, hot flushes, disturbed @entity25 persisted more often in @entity1 who remained postmenopausal after high-dose chemotherapy (P<0.05). Overall, during @entity440 @entity1 reported many symptoms. More @entity1 become postmenopausal after high-dose chemotherapy, and they remain often symptomatic after @entity440 .
